Vivek Subbiah: How Can We Be More Efficient in Early Drug Development?
Vivek Subbiah/LinkedIn

Vivek Subbiah: How Can We Be More Efficient in Early Drug Development?

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:

“How can we be more efficient in early drug development?

Operational excellence in biopharma research and early development.”

Other articles featuring Vivek Subbiah on OncoDaily.